INTRODUCTION
============

Knowledge of how organisms defend themselves from other organisms has accumulated as the biological sciences have progressed. Currently, the concepts of 'innate' and 'adaptive' defense mechanisms are used to describe all of the complex and multi-layered biological conflicts between invading and host organisms. Defensins are innate defense molecules of ancient origin that can be traced back to organisms from approximately 500 million years ago ([@b30-bt-26-242]; [@b100-bt-26-242]; [@b169-bt-26-242]). The history of the discovery of human defensins has been reviewed elsewhere ([@b6-bt-26-242]; [@b71-bt-26-242]; [@b100-bt-26-242]). In this review, we focus on studies contributing to the practical application of human defensins as antivirals.

Defensins are known for their antimicrobial functions as innate defense molecules ([@b46-bt-26-242]). However, regardless of their effectiveness against certain human pathogens in different experimental settings, infections caused by these pathogens cannot be fully cleared without the adaptive immune system, which we know much about and have the ability to modify to defend ourselves from specific pathogens. Many bacterial and viral diseases have been effectively eliminated by vaccinations or therapeutic antibodies, attesting to our competence in making use of the adaptive immune system. The innate immune system has not been harnessed to target specific pathogens, although attempts have been made ([@b141-bt-26-242]; [@b97-bt-26-242]; [@b155-bt-26-242]). Due to the relative nonspecificity of the targets of defensins compared to those of the adaptive arm, antiviral applications of defensins are conceptually ideal for defense against different viral infections. Although vaccines are considered the best prophylactic measure against microbial pathogens, the development of vaccines for certain viruses, such as human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), and dengue virus (DENV), has been challenging and has defied decades of effort ([@b136-bt-26-242]; [@b108-bt-26-242]; [@b102-bt-26-242]). Moreover, although a dengue virus vaccine was approved recently, there are still issues of the risk and benefit balance due to the complex disease mechanism, which involves cross-subtype immune responses ([@b31-bt-26-242]; [@b118-bt-26-242]). In the case of influenza A virus (IAV), 'universal vaccines' or 'broadly neutralizing antibodies' have been of particular interest in recent years to address the problem of annual vaccine update due to ceaseless antigenic changes in the virus ([@b10-bt-26-242]; [@b101-bt-26-242]; [@b68-bt-26-242]). These problems could be solved by antigenic variation-independent, universally active defensins. However, regardless of the presence of defensins in the human body and the reported antiviral effects of defensins against viruses, such as HIV ([@b12-bt-26-242]; [@b80-bt-26-242]; [@b105-bt-26-242]; [@b13-bt-26-242]; [@b126-bt-26-242]; [@b156-bt-26-242]; [@b144-bt-26-242]; [@b34-bt-26-242]; [@b114-bt-26-242]; [@b50-bt-26-242]) and IAV ([@b17-bt-26-242]; [@b75-bt-26-242]; [@b47-bt-26-242]; [@b115-bt-26-242]; [@b131-bt-26-242]; [@b146-bt-26-242]; [@b23-bt-26-242]; [@b81-bt-26-242]), individuals succumb to these viruses. In this review, we provide a brief overview of defensins and discuss the feasibility of using human defensins against various viral infections. We then discuss the need for strategic approaches based on a conceptual framework for the potential application of defensins for antiviral defense.

DEFENSINS
=========

Defensins belong to the category of antimicrobial peptides (AMPs), which have a non-enzymatic inhibitory effect on a broad spectrum of microorganisms. As the need for self-defense is universal, AMPs are universally present in organisms in one form or another. There have been detailed reviews on AMPs and defensins ([@b6-bt-26-242]; [@b35-bt-26-242]; [@b71-bt-26-242]; [@b63-bt-26-242]; [@b74-bt-26-242]; [@b56-bt-26-242]; [@b100-bt-26-242]; [@b153-bt-26-242]; [@b151-bt-26-242]; [@b152-bt-26-242]), and there are databases dedicated to AMPs ([@b100-bt-26-242]).

Three different types of defensins, including α-, β- and θ-defensins, have been identified thus far. Of these, α-defensins were first isolated in the early 1980s, when they were given names such as 'human neutrophil peptide' (HNP) ([@b36-bt-26-242]), with the term 'defensin,' first used in 1985 ([@b71-bt-26-242]), replacing earlier names. Not all mammals express all types of defensins. Although mice are a commonly used animal model, α-defensins are not expressed in mouse neutrophils ([@b29-bt-26-242]). β-Defensins are relatively broadly expressed among mammals, but θ-defensins are only expressed in nonhuman primates ([@b38-bt-26-242]). Defensins are characterized as amphipathic peptides with a net positive charge and three pairs of disulfide-bond-forming cysteines ([Fig. 1](#f1-bt-26-242){ref-type="fig"}). Amphipathicity, the presence of disulfide bonds, and the positive charge of defensins all appear to be important to the function of defensins, with individual defensins exhibiting differential effectiveness against various targets ([@b35-bt-26-242]). One of the direct and irreversible effects that defensins have on target organisms is membrane disruption ([@b72-bt-26-242]). Defensins have antiviral effects on both enveloped and non-enveloped viruses, and membrane disruption is presumed to be one of the antiviral mechanisms of defensins against enveloped viruses, similar to the antibacterial mechanism, but this has not been shown directly ([@b17-bt-26-242]). The other antiviral mechanism of defensins appears to be based on their specific binding to certain viral proteins or the non-specific lectin-like binding to the envelope glycoproteins of viruses ([@b123-bt-26-242]; [@b91-bt-26-242]; [@b124-bt-26-242]; [@b43-bt-26-242]; [@b32-bt-26-242]; [@b132-bt-26-242]). Given this mechanism, the inhibitory effects of defensins can be attributed to the blocking of the fundamental interaction between influenza glycoprotein hemagglutinin and cellular receptor sialic acid ([@b75-bt-26-242]). Specific or lectin-like binding of defensins to cellular receptors can also interfere with the cell signaling required for successful replication of the viruses ([@b21-bt-26-242]). In addition, with respect to the effects of defensins on viral entry and replication, they appear to participate in the enhancement of the adaptive antiviral responses by attracting antigen-presenting cells (APCs) to the sites of infection and stimulating them ([@b112-bt-26-242]; [@b114-bt-26-242]).

Humans express only α- and β-defensins and harbor pseudogenes of θ-defensins. There are six human α-defensins (HADs), which are abbreviated as HNP1, HNP2, HNP3, HNP4, HD5, and HD6 ([@b153-bt-26-242]). HADs are small peptides approximately 30 amino acids in length after being processed from the prepropeptides that contain an amino-terminal signal sequence, an anionic propiece and a carboxy-terminal mature peptide. The expression of 11 human β-defensins (HBD) has been observed in humans, although a computational search of the human genome has identified at least 31 β-defensin genes ([@b117-bt-26-242]). HBDs are also synthesized as prepropeptides, the mature forms of which are approximately 35--50 amino acids in length ([@b39-bt-26-242]). HADs and HBDs are structurally conserved in spite of their significant differences in genetic sequences ([@b53-bt-26-242]; [@b129-bt-26-242]). HADs are primarily expressed, constitutively, in granulocytes (HNP1, HNP2, HNP3, HNP4) and in the intestinal Paneth cells (HD5 and HD6). The major expression sites of HBDs are in the epithelial cells of various organs. Although all HADs have been studied, only four HBDs (HBD1-4) have been extensively studied. Of these, HBD1 and HBD4 are constitutively expressed in epithelial cells. HBD1 expression is also induced in various human peripheral blood mononuclear cells by enveloped viruses ([@b113-bt-26-242], [@b112-bt-26-242]). Viruses, bacteria, microbial products, and pro-inflammatory cytokines, such as interleukin-1β (IL-1β) and tumor-necrosis factor (TNF), induce the expression of HBD2 and HBD3 in various cells ([@b168-bt-26-242]; [@b153-bt-26-242]). Bacteria also induce the expression of HBD4 ([@b85-bt-26-242]) ([Table 1](#t1-bt-26-242){ref-type="table"}).

ANTIVIRAL ACTIVITIES OF DEFENSINS
=================================

The antiviral activities of human defensins have been studied on various viruses, as summarized in [Table 1](#t1-bt-26-242){ref-type="table"}. Herpes simplex virus (HSV) was one of the first viruses to be studied for the antiviral activity of HADs and showed the highest susceptibility to HADs among the viruses tested ([@b17-bt-26-242]), while HIV is the most studied target of defensins. The mechanism of the antiviral effect of defensins depends on the type of virus and is not as straightforward as the antibacterial mechanism of direct irreversible inactivation through membrane disruption ([@b72-bt-26-242]). It was recognized early on that the presence of serum or serum albumin affects the antiviral effects of defensins *in vitro* ([@b17-bt-26-242]; [@b13-bt-26-242]); therefore, the physiological significance of the antiviral effects of defensins remains unclear. It has been even suggested that the antiviral effects of defensins may be a side effect of the antibacterial effects of the peptides ([@b6-bt-26-242]).

It is difficult to determine whether defensins are critical for antiviral defense in humans, as we can only extrapolate from studies using mouse models. A murine β-defensin 1 (MBD1)-deficient mouse model showed that MBD1, the murine counterpart of HBD1, participated in the protection of mice from influenza infection via a mechanism other than the inhibition of viral replication ([@b112-bt-26-242]). Another study using a mouse model that was deficient in activated α-defensins in the small intestine showed that Paneth cell α-defensins, the murine counterpart of HD5 and HD6, protected mice from oral infection of mouse adenovirus 1 (MAdV-1). However, despite the *in vitro* neutralization activity of Paneth cell α-defensins, their absence had no effect on the kinetics and magnitude of MAdV-1 dissemination to the brain, although it did delay a protective neutralizing antibody response ([@b42-bt-26-242]). These studies suggest that the inhibition of virus replication by defensins *in vitro* might not necessarily be relevant *in vivo*. With respect to the antiviral application of defensins, an understanding of the enhancement of the adaptive immunity by defensins in response to infecting viruses appears to be crucial.

CAN WE TAKE ADVANTAGE OF HUMAN DEFENSINS FOR ANTIVIRAL DEFENSE?
===============================================================

Regardless of the *in vitro* antiviral effects of human defensins against HIV and IAV, humans still become infected with these viruses and suffer from the illnesses they cause. This is the premise upon which we seek to identify a way to take advantage of human defensins for antiviral defense. We found that the available *in vivo* studies that have been conducted are very limited. Hence, we must draw clues to answer this question from the scant published data, which may support either an optimistic or a pessimistic perspective.

As a prophylactic measure
-------------------------

Many *in vitro* studies ([Table 1](#t1-bt-26-242){ref-type="table"}) have shown that defensins have antiviral activities. The first question for the application of defensins for antiviral defense may be how they would be better used as a prophylactic or a therapeutic. Constitutively expressed HADs and HBDs are natural prophylactic measures but are not sufficient to fully protect us from viral infections. Many viruses have been reported to induce the expression of defensins ([@b104-bt-26-242]; [@b148-bt-26-242]; [@b66-bt-26-242]; [@b9-bt-26-242]; [@b112-bt-26-242]; [@b127-bt-26-242]; [@b59-bt-26-242]; [@b11-bt-26-242]), regardless of the ability of the induced defensin to block infection by viruses. The question is whether more defensins -- either constitutive or virus infection-induced -- would help clear the virus. [@b119-bt-26-242] showed that HBD3 enhanced the production of interferon-β (IFNβ) in response to polyinosinic:polycytidylic acid (poly I:C), a surrogate for viral double-stranded RNA, in both human and mouse primary cells. This finding was recapitulated in mice expressing a transgene encoding HBD3, where HBD3 was shown to use the same murine counterpart receptor CCR2 in mice ([@b109-bt-26-242]). Their results suggest that an excess amount of defensin expression may have a significant effect on the response to viral infections. The closest example of the prophylactic overexpression of defensins was reported by [@b77-bt-26-242], who showed that murine defensin-overexpressing mice were protected from a lethal IAV infection. In this study, they intramuscularly injected mice with a liposome-encapsulated MBD1-MBD3 overexpression construct 36 h prior to an IAV challenge infection. In this experiment, a reduction of the viral lung titer in mice injected with the MBD1-MBD3 overexpression construct was observed. This result might be considered a proof of principle, suggesting that a prophylactically administered excess amount of relevant human defensins may be able to similarly reduce the viral titer in humans infected with a virus.

However, the advantages and disadvantages of continuously supplying additional defensins to humans should be carefully analyzed. High concentrations of HAD can induce cytotoxicity ([@b145-bt-26-242]). Although a high concentration of HBD appears not to have a cytotoxic effect *in vitro* ([@b93-bt-26-242]), studies on the copy number variations of HBD genes suggest that higher copy numbers of HBD genes, and thus a higher expression of HBD, can be associated with diseases such as psoriasis ([@b79-bt-26-242]). Human defensins also have effects on the tumor microenvironment, both promoting and repressing tumor growth ([@b125-bt-26-242]). The potential of enhancing certain viral infections ([@b107-bt-26-242]) while inhibiting others cannot be ruled out.

Clearly, there are risks to the continuous supply of excess defensins. Another potential concern regarding continuously supplying excess amounts of defensins is the generation of multiple resistant microorganisms to defensins. Some consider the difficulty of developing resistance as the greatest advantage of using AMPs, such as defensins, reasoning that microbes need to 'redesign' their membrane lipid composition to develop resistance to AMPs ([@b83-bt-26-242]). However, since most antiviral activities of defensins involve mechanisms other than the direct irreversible disruption of the viral membrane, the escape of original target viruses from the antiviral effects of defensins cannot be ruled out. It was shown that bacterial resistance to AMPs could develop when continuously exposed to an AMP ([@b98-bt-26-242]). However, in real-life infections, the mobilization of the adaptive arm of the immune system against the target pathogen is likely to occur earlier than the development of resistance to defensins in the target pathogen. The evolutionary longevity of defensins may be proof of this. At any rate, the adjuvant activity of defensins might not be affected, since that involves host cells.

It is apparent that the continuous supply of certain defensins to prevent infections from certain target viruses requires a thorough analysis of the ramifications, which is separate from whether the *in vitro* efficacy of this approach could be recapitulated *in vivo*. A question that may prove challenging to answer is whether a prophylactic application of defensins, other than a continuous supply, can serve as a one-shot vaccination in the case of adaptive defense.

As a therapeutic measure
------------------------

The hit-and-run therapeutic application of defensins might avoid the problems associated with their continuous supply. However, whether there is an advantage to the application of defensins as a therapeutic measure against a virus is another question. We may extrapolate from a few relevant *in vivo* studies using animal models. Defensin-deficient mouse models ([@b112-bt-26-242]; [@b42-bt-26-242]) are similar to prophylactic models since they allow the presence or absence of defensins at the time of target virus infection to be studied. Furthermore, in these models, the inhibition of viral infections observed *in vitro* was not recapitulated *in vivo*. To be truly therapeutic, externally or artificially supplied defensins should be able to reduce the replication of a target virus as observed *in vitro*. In a *Pseudomonas aeruginosa* infection model of burn-wounded mice ([@b97-bt-26-242]), a local transfer of allogeneic cells infected with an HBD4-expressing Newcastle disease virus vector was used as an effective therapeutic application. Others also showed the feasibility of an adenovirus-mediated human defensin gene delivery as an antibacterial therapy ([@b87-bt-26-242]). We have not found reports of overexpression of human defensins as a therapeutic intervention method against a viral infection in animal models.

The excess supply of therapeutic defensins derived independently of eukaryotic cells might be another approach. The chemical synthesis of human defensins ([@b106-bt-26-242]; [@b64-bt-26-242]; [@b160-bt-26-242], [@b157-bt-26-242]; [@b49-bt-26-242]; [@b139-bt-26-242]) and the purification of bacterially expressed human defensins ([@b162-bt-26-242], [@b163-bt-26-242]) have been reported. The disulfide bonds and molecular structures of defensins appear not to be critical for their antibacterial functions ([@b82-bt-26-242]; [@b54-bt-26-242]; [@b18-bt-26-242]; [@b121-bt-26-242]) or cytotoxic effects ([@b65-bt-26-242]) but do affect antiviral or host cell-mediated activity, such as the chemotactic activity against immature dendritic cells (DCs) ([@b158-bt-26-242]; [@b3-bt-26-242]). Folding of the peptides can be an issue in the cases of chemical or bacterial syntheses, since the pro-segments of unprocessed defensins were shown to have an impact on folding ([@b159-bt-26-242]), which, again, affects the antigenicity of the molecules ([@b70-bt-26-242]). The preservation of the native forms of human defensins, either chemically synthesized or bacterially expressed, may be crucial to prevent potential unnecessary immunological responses of the human body from recognizing the externally supplied defensins as 'foreign' molecules.

There are scant examples of *in vivo* applications of excess amounts of human defensins that are produced in bacteria or chemically synthesized as an antiviral defense. In one study, Wang *et al*. used a murine model of vaginal HSV infection ([@b141-bt-26-242]) and observed that chemically synthesized HD5, treated either prophylactically 1 h prior to infection or therapeutically 24 h post-infection, reduced viral titers. There are also few examples of the use of non-human defensins in mouse models ([@b7-bt-26-242]; [@b154-bt-26-242]). One such example was an evaluation of a synthetic θ-defensin in a murine model of HSV-1 keratitis ([@b7-bt-26-242]). In this experiment, the application of the synthetic defensin before an infection reduced the viral titer, but not after an infection, suggesting the ineffectiveness of this approach as a therapeutic measure. It is not clear whether the lack of a therapeutic effect of θ-defensin, a nonhuman primate defensin, is due to a lack of its murine ortholog, which could have resulted in lack of a cellular receptor-mediated adjuvant-like activity. [@b58-bt-26-242] used bacterially expressed recombinant MBD3 (rMBD3) to test its protection of mice from a lethal infection of IAV. Treatment of mice began 12 h post-infection and was performed once per day for three weeks. Protection was observed to be dose-dependent, where the viral titer in the bronchoalveolar lavage fluids was reduced and a 10 mg/kg/day tail vein injection of rMBD3 provided 80% protection. Although rMBD3 blocked the virus binding and entry step rather than the subsequent stages of an ongoing infection *in vitro*, rMBD3 enhanced virus-induced expression of IL-12 and IFNγ in a dose-dependent manner while downregulating virus-induced expression of IFNα *in vivo*. IL-12 and IFNγ promote the differentiation of Th0 cells to Th1 cells and the activation of cytotoxic T-lymphocytes and natural killer (NK) cells ([@b143-bt-26-242]), which play important roles in removing virus-infected cells. It appears that not only the inhibition of IAV entry but also the modulation of cell-mediated adaptive and innate immune responses resulted in *in vivo* therapeutic efficacy of the externally administered defensins. LeMessurier *et al*. also used purified rMBD4 in a mouse model of IAV infection ([@b76-bt-26-242]), where the concurrent intranasal administration of rMBD4 and infection of IAV reduced the viral titer and increased IFNγ expression. The question is whether these mouse model studies are translatable to humans. At least one defensin, MBD4, was shown to be interchangeable with its human counterpart with respect to its chemokine receptor usage ([@b109-bt-26-242]). There is a clear need of further studies before the realization of the therapeutic application of defensins for an antiviral defense. With what is currently known, we can consider the directions of future emphasis: 1) elaboration of a murine model of defensin gene delivery-mediated temporary overexpression, a constructive exaggeration of the natural process, to eliminate the many unknowns associated with the application of defensins derived independently of eukaryotic cells; 2) elaboration of the translatability of murine models of eukaryotic cell-independently derived human defensins to humans. These two approaches are expected to complement each other.

Strategic considerations: potential target viruses and antiviral mechanisms
---------------------------------------------------------------------------

Aside from economic considerations, which we have not discussed, the formidable amount of work needed before the realization of the application of human defensins as antivirals is daunting. Basic research on the application of human defensins as antivirals towards specific target viruses would accelerate the realization of this goal. We arbitrarily name four RNA viruses that might be worth these 'directed' efforts: HIV, IAV, RSV, and DENV. Several viruses have been studied as targets of the antiviral activities of defensins ([Table 1](#t1-bt-26-242){ref-type="table"}), most likely because of the availability, 'model' status, or 'popular' status of the virus. It appears that HIV and IAV are popular models, but a full understanding of these viruses still defies us despite a mountain of research data. In addition to HIV and IAV, we have chosen RSV and DENV as potential targets worth focusing on. The difficulty in developing a broadly effective vaccine against these viruses after decades of effort might justify our exploration of these viruses as targets of the antiviral applications of defensins ([@b10-bt-26-242]; [@b136-bt-26-242]; [@b31-bt-26-242]; [@b96-bt-26-242]; [@b108-bt-26-242]; [@b102-bt-26-242]). However, since studies on the antiviral effects of human defensins against RSV and DENV are scarce, our discussion of this matter is largely an extrapolation of potentially related studies and of the required further studies.

Cell-independent antiviral effects of defensins
-----------------------------------------------

There are multiple antiviral mechanisms of human defensins, of which different mechanisms are applicable to different viruses. All of the antiviral mechanisms that produce a reduction of virus infection can conceptually be applied as therapeutic measures. One such mechanism is the heparin/heparan sulfate proteoglycan (HSPG)-binding activity of defensins, which inhibits viral binding and entry into the cells. Defensins are positively charged and have lectin-like glycan-binding activities ([@b48-bt-26-242]; [@b73-bt-26-242]; [@b120-bt-26-242]; [@b19-bt-26-242]; [@b50-bt-26-242]). Several enveloped viruses, including HIV, RSV, and DENV, are known to bind the negatively-charged HSPG ([@b170-bt-26-242]). [@b48-bt-26-242] showed through *in vitro* studies of HADs and HBDs that only those binding to either glycoprotein B (gB) or heparan sulfate inhibited HSV. They further showed that in a mouse model of lethal vaginal HSV infection, pretreatment of chemically synthesized HD5 increased the survival rates of the infected mice. HD5 bound to gB, but not heparan sulfate, with high affinity *in vitro*. Although the *in vivo* study using a mouse model was only conducted with HD5, it might be extrapolated for other defensins that were effective *in vitro*. In reality, this type of treatment would be mostly given as a therapeutic measure rather than as a pretreatment. [@b141-bt-26-242] showed the therapeutic efficacy of HD5 in a similar model. However, studies using other defensins that have higher affinities to HSPG and lower affinities to viral glycoproteins than those of HD5 might have been more informative considering the broader generality of HSPG than individual viral proteins. Studies using other HSPG-binding viruses, such as HIV, RSV, and DENV, would also help determine the therapeutic potential of human defensins against these viruses. A study showed that positively charged C-terminal regions of the chemokines CXCL9 and CXCL12γ bound with HSPG and exhibited antiviral activity against DENV, HSV, and RSV ([@b135-bt-26-242]). These results should encourage further studies of the antiviral activities of positively charged human defensins in similar contexts.

Cell-dependent antiviral effects of defensins
---------------------------------------------

Inseparable from any approach of the application of human defensins is the adjuvant-like activity of defensins. The adjuvant-like activities of defensins involve the recruitment of the host innate and adaptive immune cells to the sites of infection. This activity adds another layer to the inhibitory activity of defensins in addition to the blocking of viral entry (i.e., by binding to HSPG) and/or intracellular replication. It was shown that MBD2 acts directly on immature DCs as an endogenous ligand for Toll-like receptor 4, inducing the upregulation of costimulatory molecules and DC maturation, a link between innate and adaptive immune responses ([@b5-bt-26-242]). The adjuvant-like function of MBD2 in a murine model of influenza vaccination was also shown ([@b137-bt-26-242], [@b138-bt-26-242]). Although these findings are mainly based on studies using murine models and murine defensins, a report showed that HBD2, HBD3 and their murine orthologs were chemotactic to CCR2-bearing human cells as well as murine cells ([@b109-bt-26-242]). Indeed, [@b86-bt-26-242] showed an adjuvant-like effect of HBD2 and HBD3 on the immune responses to the gp41 antigen of HIV in a mouse model. This finding suggests that human defensins may have adjuvant-like activities in humans similar to those observed for murine defensins.

Experiments showing the *in vivo* reduction of viral titers due to externally supplied or overexpressed defensins ([@b58-bt-26-242]; [@b141-bt-26-242]; [@b77-bt-26-242]; [@b76-bt-26-242]), either as a therapeutic or a prophylactic, are rare. Even the results of these experiments, due to the nature of *in vivo* experimentation, cannot be interpreted straightforwardly. In these experiments, it is difficult to determine whether the reduction is due to the direct effect on virus replication or indirect effects on the host, such as interferon production ([@b119-bt-26-242]) or an enhancement of the adaptive arm of the immune system by attracting memory T cells, macrophages, monocytes and dendritic cells through CCR2 and CCR6 binding ([@b165-bt-26-242], [@b164-bt-26-242]; [@b109-bt-26-242], [@b110-bt-26-242]). Ultimately, determining which part plays a larger role in the eventual reduction of the viral titer might be important with respect to providing clues for further experiments. The comparison of murine defensin-deficient mouse models ([@b112-bt-26-242]; [@b42-bt-26-242]) and excess murine defensin mouse models clearly shows that a protective efficacy beyond the natural innate and adaptive responses requires an excess amount of defensins ([@b58-bt-26-242]; [@b77-bt-26-242]).

Standalone application of adjuvant-like activity of defensins
-------------------------------------------------------------

Since an adjuvant effect depends on the host immune system and not an individual virus type, the standalone application of the adjuvant-like activity of defensins, apart from their applications as conventional vaccine adjuvants, could truly be a broad-spectrum antiviral measure. We postulate the likely standalone applications of the adjuvant-like activity of defensins ([Fig. 2](#f2-bt-26-242){ref-type="fig"}), one of which is the 'therapeutic adjuvant' concept. [@b42-bt-26-242] observed delayed neutralizing antibody responses against locally infected viruses in a mouse model of local murine defensin deficiency. If defensins accelerate adaptive immune responses, this may occur while there is an ongoing infection. The concept of the 'therapeutic adjuvant' activity of defensins is in line with the process of natural immunization by the infecting viruses. However, in the presence of excess defensins, viral replication may be quickly contained by the faster mobilization of the adaptive immune responses and cell-mediated innate immune responses. [@b42-bt-26-242], using a localized gut Paneth cell α-defensin deficiency and oral MAdV-1 infection in mice, suggested that the adjuvant role of defensins has a localized impact at the viral infection site. Among the aforementioned studies, the example of the lack of efficacy of the therapeutic excess supply of primate θ-defensin in a murine model of HSV-1 keratitis ([@b7-bt-26-242]), and the example of the efficacy of the therapeutic treatment of lethally IAV infected mice with a murine defensin ([@b58-bt-26-242]), might be considered supporting evidence of the concept of therapeutic adjuvant activity of defensins as experimental 'negative (lack of relevant chemokine receptors for primate θ-defensin in mice) and 'positive' (presence of relevant chemokine receptors) controls, respectively. Further studies exploring the extent of the activities of defensins added post-infection in accelerating the mobilization of adaptive immune responses against the proposed target viruses, HIV, IAV, RSV, and DENV, might be illuminating for potential therapeutic applications. Experimental data suggest, as scant as they are, that the therapeutic adjuvant activity of defensins in the setting of virus infection leads to the production of Th1-promoting cytokines ([@b58-bt-26-242]; [@b76-bt-26-242]). Since the increased production of Th1 cytokines is associated with a better prognosis for a recovery from RSV infection, which is a serious problem in young children ([@b94-bt-26-242]; [@b95-bt-26-242]; [@b14-bt-26-242]), an *in vivo* experiment showing protection of an RSV-infected animal by a therapeutic defensin treatment would be especially relevant.

An extension of the concept of a 'therapeutic adjuvant' is the defensin-enhanced efficacy of therapeutic antibodies. Demirkhanyan *et al*. showed that a subinhibitory concentration of HNP1 in the presence of serum, while providing only a modest inhibitory effect on HIV-cell fusion, prolonged the exposure of functionally important transitional epitopes of HIV-1 gp41 on the cell surface ([@b20-bt-26-242]), markedly enhancing viral sensitivity to neutralizing anti-gp41 antibodies. This aspect of defensins has implications beyond the enhancement of the efficacy of therapeutic antibodies. The enhanced immune responses towards neutralizing antibody generation would lead to a better uptake of the antigen by neutralizing epitope-specific B cell receptor (BCR)-bearing B cells, and enrichment of these B cells by proliferation results in better generation of neutralizing antibodies ([@b161-bt-26-242]; [@b140-bt-26-242]). Similar aspects of defensin activity might be explored against other target viruses, especially if neutralizing epitopes of flaviviruses, such as DENV, were shown to be revealed by the molecular 'breathing' (changing structural conformation) of viral surface proteins ([@b25-bt-26-242], [@b26-bt-26-242], [@b24-bt-26-242]). One of the challenges to DENV vaccine development is the non-neutralizing and disease-enhancing cross-reactivity of antibody responses among the subtypes of DENV. The 'original antigenic sin'-based preferential non-neutralizing cross-reactive memory responses to the previously infected subtype hinder fresh immune responses to the neutralizing epitopes of the newly infecting subtype ([@b111-bt-26-242]; [@b96-bt-26-242]). If defensins could expose the neutralizing epitope, during the 'breathing' of the surface molecules of DENV, to the neutralizing epitope-specific BCR-bearing B cells, fresh immune responses might gain access to the antigen -- an escape from the monopolized grip of the cross-reactive 'original antigenic sin.' There is no study showing an interaction between human defensins and surface proteins of DENV. However, the N-glycans of the envelope glycoprotein of DENV have been reported to be crucial for DC-SIGN-mediated infection of the virus ([@b2-bt-26-242]). There is the possibility of an interaction between the surface glycoproteins of DENV and a lectin-like human defensin ([@b75-bt-26-242]). The possibility of a breakthrough result makes testing this potential interaction tempting. Further studies on RSV in this regard might also be warranted due to a recent study in which antibodies recognizing a pre-fusion conformation-specific neutralizing epitope on the RSV fusion protein were shown to neutralize both RSV A and B subgroups ([@b89-bt-26-242]). In the case of IAV, changing glycosylation patterns in the globular head of the hemagglutinin (HA) protein is recognized as one of its immune evasion mechanisms ([@b62-bt-26-242]; [@b130-bt-26-242]). While universally conserved epitopes of HA subtypes are the targets of universally protective vaccine designs, bypassing the highly variable and immunodominant globular head regions of HA is a major challenge ([@b67-bt-26-242]; [@b55-bt-26-242]). Considering the binding activity of lectin-like glycoproteins, blocking of the glycosylated globular head regions by defensins to enhance the availability of the subdominant conserved stalk regions of HA to the specific B cells is also a tempting possibility.

Another possible use of the adjuvant-like activity of defensins is as a prophylactic, which might provide a vaccine-like effect, the feasibility of which we posed as a challenging question earlier. Since there is no direct study dealing with this likelihood *in vivo*, we propose a framework from a thought experiment based on very few available indirect studies. Interesting prospects emerge when we put the experiments of [@b77-bt-26-242] in the context of those of [@b119-bt-26-242] ([Fig. 2](#f2-bt-26-242){ref-type="fig"}). The reduction in the lung titer of intranasally infected IAV by the intramuscular injection of a defensin overexpression construct observed by [@b77-bt-26-242] might be considered as a prophylactic systemic overexpression of defensins limiting incoming virus replication. The systemic presence of defensins might have 'primed' the body for enhanced local antiviral responses. The defensin-exacerbated virus-induced production of type I interferon (IFN I) by the infected cells and plasmacytoid dendritic cells (pDCs) might have inhibited viral replication and mediated the chemoattraction of immune cells to the lungs for antigen presentation and infected cell removal. The role of enhanced systemic basal levels of IFNβ due to the systemic presence of overexpressed defensins, as shown by [@b119-bt-26-242] may be more relevant in a real-life infection with a small viral inoculum. How defensin-overexpressing mice attained higher systemic basal levels of IFNβ is debatable. Commensal microbial flora or infectious but non-disease-causing viruses in the environment possibly playing a role should not be ruled out ([@b61-bt-26-242]). IFN I production from defensin-mediated DNA uptake and signaling ([@b133-bt-26-242]) may also have been the source of the elevated basal level of IFN I. If the results of [@b119-bt-26-242] and [@b77-bt-26-242] are translatable to humans, an extrapolation of those results might be used in the vaccine-like prophylactic application of defensins in antiviral defense. If the results of [@b119-bt-26-242] were to be recapitulated with actual RNA viruses rather than the surrogate poly I:C, the defensin-mediated IFN induction in RNA viruses could be applied to all of the proposed target viruses (HIV, IAV, RSV, and DENV) and eventually be extended to other viruses. It is conceivable that a shot of a defensin expression construct could be given in preparation for a flu season, prior to travel to a DENV-endemic area, or to protect young children from RSV. IAV has been the cause of several pandemics in recorded history, including the latest 2009 pandemic and the well-known 1918 pandemic, which caused some 50 million deaths ([@b90-bt-26-242]; [@b142-bt-26-242]). The problem with IAV is that we can never confidently predict the subtype of IAV of the next pandemic, which would allow the preparatory stockpiling of vaccines. The concept of a 'defensin vaccine,' if realized, would be ideal to address this uncertainty. IAV and RSV were shown to be as sensitive as vesicular stomatitis virus (VSV), a well-known IFN I sensor, to IFN I produced upon poly I:C treatment *in vitro* and *in vivo* ([@b51-bt-26-242]). DENV was also shown to induce and be inhibited by type 1 IFN ([@b69-bt-26-242]; [@b8-bt-26-242]; [@b57-bt-26-242]; [@b9-bt-26-242]; [@b127-bt-26-242]). Although all of these viruses have their own counter-IFN measures, they are not efficient in replicating in interferon-pretreated cells ([@b122-bt-26-242]; [@b22-bt-26-242]; [@b45-bt-26-242]; [@b78-bt-26-242]; [@b147-bt-26-242]), and a prophylactic 'defensin vaccination' might prime the body to an IFN-pretreated state.

Temporary overexpression of defensins mediated an exaggeration of a viral induction of IFN. The subsequent co-antiviral activity of defensins and IFN can be observed in the same light as clinically practiced IFN therapies ([@b99-bt-26-242]; [@b92-bt-26-242]; [@b37-bt-26-242]). However, while the IFN therapies are used to control ongoing, full-blown infections, the defensin vaccination scheme is designed to contain the viral infection at the initial stage of infection, similar to how a vaccination contains the cognate viral infection at the initial stage by mobilizing memory immune responses against the virus. One might ask why we have not evolved to have defensin levels similar to the prophylactically or therapeutically effective levels observed in animal experiments. Hard-wired constitutively high levels of defensins might not be beneficial. The key to this 'defensin vaccine' concept is in manipulating the genetically programmed basal or induced levels of defensin expression and providing a 'shot' of a defensin overexpression construct when needed, which would last only for a limited time. One might ask why human defensins should be used for such a standalone adjuvant-like activity and not other chemical or microbial adjuvant products ([@b116-bt-26-242]). The greatest advantage of human defensins may be that they are peptides, enabling us to sustain their controlled production *in vivo* through gene expression.

The postulated scheme of the vaccine-like prophylactic application of defensins may appear to be an oversimplification, and admittedly, there are many leaps in reasoning that are necessitated by a lack of experimental data. Although prophylactic measures are considered better than therapeutic measures, we are currently in the dark as to which of the proposed standalone applications of the adjuvant-like activity of defensins will likely be realized. Needless to say, many studies are needed to fill in the details. Each step of the scheme should be concretely established in animal experiments before a clinical trial. There have been clinical trials of AMPs from diverse sources and their derivatives, primarily for topical antibacterial or antifungal purposes ([@b167-bt-26-242]; [@b33-bt-26-242]). There exists a research gap between the antibacterial/antifungal and the antiviral applications of defensins. Since the antiviral mechanisms of defensins are not as straightforward as the antibacterial mechanisms, and an antiviral application requires the systemic administration of defensins, additional basic research is needed before a clinical trial of antiviral defensins can be launched.

CONCLUSIONS
===========

We have briefly reviewed human defensins and studies of the antiviral applications of defensins. Our review suggests a need for further exploration of the adjuvant-like activity of human defensins. We find that the natural levels of constitutive or virally induced defensins can provide a minimal level of defense against infecting viruses. We propose a prophylactic 'defensin vaccine' concept of a planned and controlled overexpression of defensins, which is akin to manually operating the 'safety lock' of natural defensin expression program as needed. Our proposal is in the same conceptual line of Edward Jenner's 'vaccination' ([@b88-bt-26-242]), which took advantage of the inherent human immune system. At this point, our proposal is only a conceptual guideline. Further studies will give weight to either the acceptance or disposal of our proposal.
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![Structure of human β-defensin 1 (HBD1). The monomeric structure of HBD1 (PDB ID: 1IJU) ([@b53-bt-26-242]) is shown in a cartoon rendering, which was constructed using PyMOL (<https://www.pymol.org>). A three-stranded antiparallel β-sheet (green) is common in all known structures of α- and β-defensins. Three pairs of disulfide bonds that define a defensin are shown in yellow. The peptide backbone chain and the side chain residues are shown in thin lines. Basic residues, lysine and arginine, which are positively charged at a neutral physiological pH, are highlighted in a stick rendering.](bt-26-242f1){#f1-bt-26-242}

![Postulated mechanism of antiviral defense by a prophylactic defensin overexpression 'vaccine.' Local responses surrounding the infected cells after viral entry into the human body are depicted. (1) Virus infection-associated recruitment of innate and adaptive immune cells are depicted ([@b143-bt-26-242]; [@b84-bt-26-242]; [@b52-bt-26-242]; [@b16-bt-26-242]; [@b109-bt-26-242]; [@b40-bt-26-242]; [@b134-bt-26-242]). (2) Defensin expression (for induced and systemically overexpressed defensins) is depicted ([@b1-bt-26-242]; [@b28-bt-26-242]; [@b60-bt-26-242]); due to the potential cytotoxicity of excess amount of HADs, only HBDs are considered for an interventional application. (3) Viral clearance is depicted. (4) Potential role of defensins in exposing the neutralizing epitope of a virus and the potential rapid T-cell-independent neutralizing epitope-specific naive B cell activation against a virus captured by recruited B cells and dendritic cells (DCs) are postulated ([@b140-bt-26-242]; [@b128-bt-26-242]; [@b103-bt-26-242]). T-cell-dependent processes can occur similarly in the presence of T cells in the draining lymph nodes ([@b161-bt-26-242]; [@b41-bt-26-242]). Black arrows indicate processes affected by constitutively expressed or physiologically induced defensins. Orange arrows indicate the potential amplification of the processes by the overexpressed defensins. Dashed orange arrows indicate the processes not likely to be influenced by the overexpressed defensins due to the systemic nature of their overexpression. However, the concentration of locally induced defensins due to viruses and cytokines might be higher than the systemic concentration of the overexpressed defensins, and there may be a locally enhanced induction loop. Viral infection results in type I interferon (IFN I) production by infected cells and virus-stimulated plasmacytoid dendritic cells (pDCs) (1), which also produce CCL2. Viral infection also induces defensin expression (2). Defensins (2) exaggerate viral RNA-mediated IFN I induction (1). Defensins (2) can bind to CCR2 and act as chemoattractants to CCR2-expressing cells (1). CCR2-expressing monocytes (MO), macrophages (MP) and monocyte-derived dendritic cells (moDCs) respond to IFN I, CCL2, and defensins and produce further CCL2 and further recruit CCR2-expressing B, MO, MP, moDC, activated T, and natural killer (NK) cells (1). These cells produce cytokines, such as IL-12, gamma interferon (IFNγ) and tumor necrosis factor-alpha (TNFα) (1). IL-12 and IFNγ promote Th1 responses and activate cytotoxic T and NK cells (1). IFNγ and TNFα induce defensins (2). During this cycle, the innate arm of defense (IFN I, defensins, and NK cells) inhibits virus replication and removes the virus-infected cells (3). Recruited antigen-presenting cells (B, MP and moDCs) initiate the adaptive arm of defense (3). On-site T cell-independent viral antigen-specific B cell activation and antibody secretion could occur against the virus captured by recruited B cells and DCs (4). Defensin-mediated exposure of the neutralizing epitope of the virus would further enhance neutralizing epitope-specific antibody responses and viral clearance (4). Overexpressed defensins would increase systemic levels of defensins and enhance all of the processes at the location of viral infection to clear the virus, providing a memory response-like effect. Objects in the cartoon are not to scale.](bt-26-242f2){#f2-bt-26-242}

###### 

Antiviral activity of defensins

  Virus[^\*^](#tfn1-bt-26-242){ref-type="table-fn"}   Defensins           Antiviral activity
  --------------------------------------------------- ------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  BKV                                                 HNP1, HD5           Inhibition of viral attachment to the cell by directly binding to the non-enveloped virus, leading to aggregation of the virion particles ([@b27-bt-26-242]).
  HAdV                                                HD5                 Mechanism of non-enveloped virus inactivation; blocking of uncoating by binding to the capsid proteins ([@b123-bt-26-242]; [@b91-bt-26-242]; [@b124-bt-26-242]; [@b43-bt-26-242]; [@b32-bt-26-242]; [@b132-bt-26-242]).
                                                      HNP1                Reduction of adenoviral infection by more than 95% if administered at 50 μg/ml with an IC50 15 μg/ml ([@b4-bt-26-242]).
                                                      HD5, HBD1           Reduction of adenovirus infectivity ([@b44-bt-26-242]).
  HIV                                                 HBD2, 3             Oligomerization from heparin sulfate proteoglycan (HSPG)-facilitated binding of HBDs and HIV gp120 to the cell surface and reduction of HIV infectivity ([@b50-bt-26-242]).
                                                      HNP1-4              Inhibitory effect as constituents of neutrophil extracellular traps (NET) ([@b114-bt-26-242]).
                                                      HD5                 Inhibition of HIV-1 by interfering with the reciprocal interaction between the envelope glycoprotein gp120 and CD4 and downmodulating the CXCR4 co-receptor ([@b34-bt-26-242]).
                                                      HBD2, 3             Inhibition of R5 and X4 HIV infection at a physiological concentration in the oral cavity by a mechanism not involving fusion inhibition or co-receptor modulation ([@b126-bt-26-242]).
                                                      HNP1                Direct inhibition in the absence of serum and at a low MOI; inhibition of HIV replication by inhibiting PKC activation in the presence of serum and at a high MOI ([@b13-bt-26-242]). Inhibition of HIV-1 infection after viral entry ([@b12-bt-26-242]).
                                                      HNP4                Inhibition of X4 and R5 HIV-1 is more effective than HNP1-3, probably due to the lectin-independent property of HNP4. Irreversible effect on virion infectivity by binding to viral particles ([@b156-bt-26-242]).
                                                      HBD2, 3             Irreversible effect on virion infectivity by direct binding to viral particle and downmodulation of the HIV-1 co-receptor CXCR4 in peripheral blood mononuclear cells and T lymphocytic cells ([@b105-bt-26-242]).
                                                      HNP1-3              Direct inactivation of viral particles and inhibition of the target CD4 cells from supporting the virus replication ([@b80-bt-26-242]).
  HPV                                                 HD5                 Prevention of the dissociation of the viral capsid from the genome and redirection of the viral particle to the lysosome ([@b132-bt-26-242]; [@b150-bt-26-242]).
                                                                          Blocking of a critical host-protease-mediated processing site of the minor capsid protein ([@b149-bt-26-242]).
  HSV                                                 HD5                 Enhanced binding to the capsid protein gD (*in vitro*) through mutational addition of positive charges correlated with enhanced protection in a mouse model of lethal HSV-2 infection ([@b141-bt-26-242]).
                                                      HNP1-6, HBD3        Inhibition of HSV infection; HNP4, HNP6 and HBD3 prevented binding and entry, and HNP1-3, HNP5 inhibited post-entry events ([@b48-bt-26-242]).
                                                      HNP1-3              Antiviral mechanism not involving viral attachment; effective during the post-penetration period ([@b166-bt-26-242]).
                                                      HNP1-3              Direct inactivation of the virus. Addition of serum or serum albumin to the incubation mixtures inhibited neutralization of the virus by HNP1 ([@b17-bt-26-242]).
  IAV                                                 HNP1-3              Antiviral activity through induction of MxA in human gingival epithelial cells ([@b81-bt-26-242]).
                                                      HAD                 Antiviral activity of HAD in human saliva at a physiological concentration ([@b146-bt-26-242]).
                                                      HNP1-2, HD5, HBD2   Aggregation of IAV and enhanced neutrophil-mediated clearance (HBD2 activity lower than HAD) ([@b47-bt-26-242]; [@b131-bt-26-242]; [@b23-bt-26-242]).
                                                      HNP1                Inhibition of IAV replication through the inhibition of protein kinase C (PKC) activation in infected cells ([@b115-bt-26-242]).
                                                      HBD3                Blocking of viral fusion (fusion pore generation) by creating a protective barrier of immobilized surface glycoproteins from lectin-like properties of HBD3 ([@b75-bt-26-242]).
                                                      HNP1                Direct inactivation of the virus ([@b17-bt-26-242]).
  RSV                                                 HBD2                Blocking of viral cellular entry, possibly because of the destabilization/disintegration of the viral envelope ([@b66-bt-26-242]).
  VZV                                                 HBD2                Inhibition of VZV in a skin infection model ([@b15-bt-26-242]).

Abbreviations stand for: BKV, BK virus; HAdV, human adenovirus; HIV, human immunodeficiency virus; HPV, human papillomavirus; HSV, herpes simplex virus; IAV, influenza A virus; RSV, respiratory syncytial virus; VZV, varicella zoster virus.
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